[Geneco]

Our additional survival analyses demonstrated that the NVax patients admitted post-COVID-19 vaccine introduction had increased risk of mortality compared to those admitted pre-vaccine introduction (Supplementary Figure 2A). This could result from different dominant variants circulating during these different time periods (e.g. pre-Delta and Delta variants). However, Vax patients had significantly higher risk of mortality compared to both NVax groups (Supplementary Figures 2B, C).

In an attempt to control our observation, we assessed a cohort of 40 patients admitted to the hospital with non-COVID ARF. Mortality rates did not differ significantly between Vax (27%) and NVax (36%) patients (Supplementary Table S1). However, the number of patients in this cohort was also low, thereby limiting our ability to make conclusions.